Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of non-systemic, small molecule therapeutics that work in the gastrointestinal (GI), tract to treat cardio-renal, GI and metabolic diseases. The Company has developed a drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design drug candidates. Utilizing its platform, the Company discovered and designed its product candidate, tenapanor, which in preclinical and clinical studies has consistently demonstrated the ability to reduce the absorption of dietary sodium and phosphorus, both of which are key factors in the progression of kidney disease. The Company�s product candidate, tenapanor, is a small molecule, orally administered inhibitor of NHE3, a transporter of sodium in the GI tract. It and AstraZeneca AB (AstraZeneca) has evaluated tenapanor in eight human clinical trials in over 765 individuals.